ETON Stock Analysis: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$23.24
-0.21 (-0.90%)
▼
5d:
+4.12%
30d:
+34.72%
90d:
+36.55%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Distribution
ETON is up 7.0% this week, but smart money is buying puts. Top strike: $12.5 2026-04-17 with 6 OI. Put ratio: 100% View Scanner →
Strength: 8.5/10
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ETON is 7.8% above fair value ($21.56). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ETON is 7.8% above fair value ($21.56). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$50.73
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$31.50
26.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $23.24, which is considered extended relative to its 30-day fair value range of $16.90 to $21.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.9) compared to its historical average (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ETON is in a uptrend. Immediate support is located at $18.62, while resistance sits at $24.46.
Market Sentiment: ETON has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.33 (+69.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ETON is in a uptrend. Immediate support is located at $18.62, while resistance sits at $24.46.
Market Sentiment: ETON has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.33 (+69.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$16.90 -
$21.56
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BEARISH: Price extended above range (+7.8% above fair value)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 69.2% below Wall St target ($39.33)
- CAUTION: Extended 7.8% above fair value - wait for pullback
Fair Price Analysis
30-Day Fair Range
$16.90 -
$21.56
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$3.05
(13.1%)
Support & Resistance Levels
Support Level
$18.62
Resistance Level
$24.46
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.90
Wall Street Target
$39.33
(+69.2%)
Revenue Growth (YoY)
82.7%
Earnings Growth (YoY)
-12.6%
Profit Margin
-5.8%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
14.9 vs 16.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$22.38
(-4%)
2-Year Target
$21.55
(-7%)
3-Year Target
$20.75
(-11%)
3-Yr Target (if PE normalizes)
(PE: 15→17)
$23.27
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 85.7%)
$117.94
(+408%)
Base:
(SPY PE: 14.9, Growth: 85.7%)
$78.44
(+238%)
Bear:
(PE: 12.7, Growth: 85.7%)
$66.67
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.9 to 16.7
Stabilization Target:
$26.05
(+12.1%)
PE Expansion Potential:
+12.1%
Share & Embed Analysis
Last updated: March 30, 2026 8:56 AM ET
Data refreshes hourly during market hours. Next update: 9:56 AM
Data refreshes hourly during market hours. Next update: 9:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 60 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 58 HOLD |
